InMode Ltd. (NASDAQ:INMD) Receives Average Rating of "Hold" from Brokerages

Key Points

• Analysts rate InMode “Hold” on average: Of eight covering firms, six recommend holding, one recommends selling and one recommends buying. The average 12-month price target is $16.00 versus a share price of $14.79.
• InMode’s latest quarterly results met expectations, with earnings of $0.35 per share and revenue of $95.59 million, slightly above the $94.89 million consensus estimate. Net margin was 20.69% and return on equity was 11.99%.
• Institutional investors own 68.04% of the stock. Several hedge funds and investment firms recently initiated or increased positions, while Weiss Ratings maintained a “sell (D+)” rating.

Shares of InMode Ltd. (NASDAQ:INMD - Get Free Report) have been given an average recommendation of "Hold" by the eight research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $16.00.

Separately, Weiss Ratings restated a "sell (d+)" rating on shares of InMode in a report on Thursday, August 6th.

InMode Stock Down 0.1%

Shares of INMD stock opened at $14.79 on Thursday. The stock has a market cap of $850.13 million, a price-to-earnings ratio of 12.02 and a beta of 1.86. The business's fifty day moving average is $15.07 and its 200 day moving average is $14.28. InMode has a twelve month low of $12.72 and a twelve month high of $16.74.

InMode (NASDAQ:INMD - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The healthcare company reported $0.35 EPS for the quarter, meeting the consensus estimate of $0.35. InMode had a return on equity of 11.99% and a net margin of 20.69%.The business had revenue of $95.59 million during the quarter, compared to analyst estimates of $94.89 million. During the same quarter last year, the firm posted $0.47 earnings per share. The company's revenue for the quarter was up .0% on a year-over-year basis.

Institutional Trading of InMode

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Leonteq Securities AG bought a new stake in InMode in the fourth quarter worth $26,000. Quadrant Capital Group LLC increased its holdings in shares of InMode by 127.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,945 shares of the healthcare company's stock valued at $29,000 after acquiring an additional 1,091 shares in the last quarter. IFP Advisors Inc purchased a new position in shares of InMode in the 2nd quarter worth about $31,000. Advisory Services Network LLC bought a new position in InMode in the 3rd quarter worth about $37,000. Finally, Basepoint Wealth LLC bought a new position in InMode in the 4th quarter worth about $39,000. Hedge funds and other institutional investors own 68.04% of the company's stock.

About InMode

InMode Ltd. NASDAQ: INMD is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode's product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.